If WP states in the recent company announcement that new supportive capital will not be dilutive that suggests to me that he will do a TAVR deal which would involve the valve tech independently and not involve the company as such i.e. sell 60% of the TAVR for $35m which would keep us afloat and reduce our future TAVR ongoing costs without dilution. In other words sell a fraction of the company to keep the rest afloat.
Either that or he has a buyer for the infusion business which he will announce soon. I cannot help thinking that the TAVR interest is very costly to keep progressing. IF we sold 75% of this business we might reduce our costs by 50% and become profitable? We could still supply the Adapt material for the TAVR and the 4C valves as well as retaining a percentage interest in the TAVR story. At least we would survive and thrive with a P/E of 40 or more.
- Forums
- ASX - By Stock
- Why no announcements
If WP states in the recent company announcement that new...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M |
Open | High | Low | Value | Volume |
$12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 175 | $11.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.49 | 77 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 772 | 11.600 |
2 | 2000 | 11.500 |
1 | 80 | 11.250 |
1 | 500 | 11.050 |
2 | 600 | 11.000 |
Price($) | Vol. | No. |
---|---|---|
12.490 | 77 | 1 |
12.500 | 56 | 1 |
12.520 | 500 | 1 |
12.850 | 99 | 1 |
13.300 | 200 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |